-transparent.png){kind=logo}
Non-nucleoside reverse transcriptase inhibitors form the backbone of antiretroviral treatment for many HIV-infected individuals. The tolerability, pill burden and efficacy associated with this class of agents make them a frequent choice for first-line therapy. Here we review nevirapine and efavirenz in terms of efficacy, resistance and toxicity, focusing particularly on the use of nevirapine to prevent mother-to-child transmission in developing countries.
Related Publications
L Waters, and
L John, and
M Nelson
June 2000,
Annales de medecine interne,
L Waters, and
L John, and
M Nelson
June 1996,
BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation,
L Waters, and
L John, and
M Nelson
February 2003,
International journal of STD & AIDS,
L Waters, and
L John, and
M Nelson
February 2001,
Enfermedades infecciosas y microbiologia clinica,
L Waters, and
L John, and
M Nelson
June 2008,
Journal of HIV therapy,
L Waters, and
L John, and
M Nelson
November 1999,
Antiviral chemistry & chemotherapy,
L Waters, and
L John, and
M Nelson
January 2000,
MMW Fortschritte der Medizin,
L Waters, and
L John, and
M Nelson
January 2000,
Reviews in medical virology,
L Waters, and
L John, and
M Nelson
May 2003,
Seminars in liver disease,
L Waters, and
L John, and
M Nelson
August 2006,
Virologie (Montrouge, France),
